Epitalon: complete guide to the pineal tetrapeptide

Epitalon, also spelled Epithalon, also called AEDG after its amino acid sequence, is a synthetic peptide modeled on Epithalamin, a bovine pineal gland extract that Russian researchers began isolating in the late 1980s ^[2]. The synthetic version was developed at what is now the St. Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson ^[3]. The institute's program was unusual in scope: identify short peptide signals from aging organs, synthesize analogs, then test them as geroprotectors across cell lines, rodents, and eventually humans.

Khavinson's group has published on Epitalon for roughly three decades. Almost all of the human data carries his name on it. That fact matters, and we'll return to it.

The compound has no FDA approval for any indication in the United States. It's approved for clinical use in Russia, where it sits inside a broader category of "peptide bioregulators" that don't have a direct regulatory analog in Western medicine. Outside Russia, it exists primarily as a research compound and a gray-market longevity supplement.

The pineal gland is roughly the size of a grain of rice. It sits near the center of the brain, secretes melatonin in response to darkness, and, for reasons still not entirely understood, calcifies and shrinks with age. By the eighth decade of life, pineal melatonin output has typically fallen sharply.

Russian gerontology in the 1970s and 80s took the pineal seriously as an aging pacemaker. Remove it from young rats and they aged faster. Transplant a young pineal into an old rat and certain markers reversed. From that backdrop, Khavinson's group extracted Epithalamin, a peptide mixture from bovine pineal tissue, and reported lifespan extension in rodents. AEDG, the synthetic four-amino-acid peptide, was their attempt to isolate the active fragment.

This is the origin story. Worth knowing, because most of Epitalon's mechanistic claims trace back to a hypothesis about pineal aging rather than to a target identified by structural biology.

Telomeres are the repetitive DNA caps at the ends of chromosomes. They shorten with each cell division. When they get short enough, the cell stops dividing. Telomerase is the enzyme that adds telomeric repeats back on, highly active in stem cells and germ cells, mostly silent in normal somatic cells, and reactivated in roughly 85% of human cancers ^[4].

Epitalon's headline mechanistic claim is that it activates telomerase in normal cells, restoring telomere length.

The in vitro evidence is real, and recent work has sharpened it considerably. A 2025 study from Brunel University London (Al-Dulaimi et al., PMID 40908429) tested Epitalon across four human cell lines ^[5]: normal mammary epithelial cells and fibroblasts on one hand, two breast cancer lines on the other. In the normal cells, Epitalon produced dose-dependent telomere elongation through the classical pathway: upregulation of hTERT, the catalytic subunit of telomerase, followed by increased enzymatic activity.

In the cancer cells, something different happened. Telomeres still elongated, but not via telomerase. The mechanism shifted to ALT, Alternative Lengthening of Telomeres ^[6], a recombination-based pathway that the authors traced to Epitalon's apparent interaction with histone H1, decompacting telomeric chromatin.

Two pathways. One molecule. Different cell contexts.

That divergent finding is, on the cleanest read of the data, the single most important recent data point on this peptide, and not for the reason the longevity press has framed it. The clean "telomerase activator" story is more complicated than the marketing copy suggests, and the cancer-cell mechanism raises a question nobody has answered: what happens if someone with occult malignancy takes this for years?

The pineal angle isn't only historical. Epitalon does appear to stimulate endogenous melatonin output and modulate circadian gene expression, at least in the small studies that have looked.

A study of women given sublingual Epitalon reported a notable increase in melatonin production versus placebo, with measurable shifts in Clock, Cry2, and Csnk1e gene expression in lymphocytes ^[7]. The effect size is interesting; the sample size and replication status are not. One study, one group, twenty days.

Antioxidant activity shows up consistently in cell models. A 2022 paper in mouse oocytes (Yue et al., PMID 35413689) found that Epitalon at 0.1 mM reduced reactive oxygen species, preserved mitochondrial membrane potential, and reduced spindle defects in post-ovulatory aging ^[8]. The authors described these effects as comparable in magnitude to melatonin itself. A 2025 follow-up in bovine cumulus-oocyte complexes showed markers consistent with enhanced mitochondrial activity, the standard mitochondrial biogenesis markers.

These are interesting findings about a peptide acting on mitochondria and the redox environment. They're not evidence that a person taking Epitalon will live longer.

The most-cited rodent study is an Anisimov et al. paper in Biogerontology: a cohort of female SHR mice split into Epitalon and control groups, given a small subcutaneous dose for five consecutive days each month, for life.

The result was specific and worth quoting precisely. Mean lifespan did not change. Maximum lifespan and last-10%-survivor lifespan increased meaningfully (p<0.01). Chromosome aberrations in bone marrow fell substantially. Leukemia incidence dropped several-fold.

So the drug didn't make the average mouse live longer. It made the longest-lived mice live somewhat longer, and it reduced certain age-associated pathologies. That's a different claim, and a more modest one, than "Epitalon extends lifespan."

Other rodent work has gone in similar directions: tumor suppression in HER-2/neu transgenic mice, lifespan extension in Drosophila, vision preservation in a rat model of retinitis pigmentosa. There's also a less-discussed finding from a HER-2/neu frailty model showing dose-dependent effects. Lower doses helped survival; higher doses actually reduced maximum lifespan due to frailty accumulation. Regimen-sensitive. Strain-sensitive. Not a clean story.

The most rigorous human study isn't a longevity trial. It's an ophthalmology trial.

Russian researchers gave retinitis pigmentosa patients parabulbar injections of Epitalon for a course of several days, and a large majority showed visual improvement. Visual acuity gains of 0.15 to 0.20 were reported, along with measurable increases in retinal neuron response amplitudes. No side effects were documented. Whatever you make of the longevity claims, this is a real clinical signal in a specific disease, with a sample size that isn't trivial.

The circadian study mentioned above is the second main human dataset. The telomere-in-elderly observation, comparing blood-cell telomere length in patients ages 60-65 versus 75-80, with both Epitalon and Epithalamin reportedly increasing telomere length, is the third. A prospective cohort study reported substantial reductions in mortality over several years with Epithalamin (the parent bovine extract, not synthetic AEDG), with reductions rising further when combined with annual thymalin.

That mortality number is the one that gets quoted most often in longevity content. Read it carefully. It's Epithalamin, not Epitalon. It's a Russian cohort study from the same research group that developed the compound. It has no Western replication, no blinding, and no published protocol that would allow independent assessment.

One case report exists describing improvements in biological age markers after a combined Epitalon-Semax protocol in a single individual. That's a case report. It's, by definition, not evidence of efficacy.

What doesn't exist: any blinded, randomized, multicenter, controlled trial of synthetic Epitalon for any longevity endpoint, in a PubMed-indexed journal, conducted independently of Khavinson's group.

The marketing claims travel in roughly this order: lifespan extension, telomere lengthening, melatonin restoration, immune support, cognitive enhancement, "biological age reversal."

What the published evidence supports, stated conservatively:

In vitro telomere elongation in human cells: shown, with the mechanistic caveats above. Animal lifespan effects: partial, regimen-dependent, more convincing for maximum lifespan and cancer reduction than for mean lifespan. Melatonin restoration in humans: one small study, plausible mechanism, not independently replicated. Visual improvement in retinitis pigmentosa: surprisingly strong single trial, no Western confirmation. Cognitive enhancement: case-report territory.

The honest read of the data: there's more preclinical support for this peptide than for many compounds marketed as longevity agents, and considerably less human evidence than the marketing implies.

The published clinical data is, to a slightly suspicious degree, free of adverse events. The retinitis pigmentosa trial reported none. The circadian study reported none. The animal toxicology, at the doses studied, hasn't surfaced dose-limiting toxicity.

The FDA's FAERS database may include adverse event reports tagged to Epitalon, though the exact counts are difficult to verify for an unapproved compound with limited regulatory visibility. These are difficult to interpret. FAERS reports for unapproved compounds typically come from patients using multiple agents in unsupervised settings. The signal-to-noise ratio is poor.

The theoretical safety concern that actually has mechanistic backing is the one from the 2025 Brunel study: Epitalon appears to elongate telomeres in cancer cells via a non-telomerase pathway. Whether that translates to accelerated tumor progression in a person with undiagnosed malignancy is unknown. Nobody has studied it. The longevity content rarely mentions it.

There's no long-term human safety data. No multi-year pharmacovigilance program outside Russia. No population-scale exposure data of the kind that would surface rare adverse events.

Epitalon's US status moved in 2026, and the direction matters.

In late 2023, the FDA placed Epitalon in Category 2 of bulk drug substances under section 503A ^[9], the bin that effectively bars traditional compounding pharmacies from preparing a substance for individual patients. The agency cited safety concerns and insufficient clinical data.

Compounding pharmacy groups sued. A recent settlement required the FDA to send several peptides to the Pharmacy Compounding Advisory Committee for formal review rather than maintaining unilateral prohibition.

On April 15, 2026, the FDA announced that Epitalon was being removed from Category 2 ^[10]. This is not approval. It's the agency stepping back from a prohibition while the PCAC review proceeded.

That review happened on July 24, 2026. The committee voted to recommend Epitalon for the 503A bulks list — 7 in favour, 4 against, 1 abstention, with the free base and the acetate voted separately and landing the same way ^[11]. FDA's own reviewers had proposed rejecting it; the use they had evaluated was insomnia. Notably, only twelve members voted on this question, the thinnest turnout of the two-day meeting.

None of that makes Epitalon compoundable. A committee recommendation is non-binding, FDA has issued no final determination, and the substance is not on the 503A positive list — getting it there requires rulemaking, which has not begun and has no timeline. Our report on the vote has the full record. The status today is what it was in April: neither prohibited nor authorised.

Until that review concludes and formal rulemaking follows, Epitalon's legal status in the US remains awkward: not approved, no longer formally prohibited from compounding, but not cleared for legitimate compounding either. 503B outsourcing facilities can't prepare it absent specific regulatory clearance.

For sport: Epitalon does not appear to be specifically named on the WADA Prohibited List but likely falls under S0, non-approved substances banned at all times.

The list is longer than the list of what we do know.

Human pharmacokinetics: no published half-life, no absorption data comparing subcutaneous to sublingual to oral routes. Best dose for any longevity endpoint: unknown. Whether the telomere effects observed in cell culture occur in living human tissue at achievable plasma concentrations: unknown. Whether the cancer-cell ALT mechanism has any clinical relevance: unknown. Whether melatonin restoration translates to meaningful sleep, mood, or aging outcomes over years: unknown. Whether independent Western groups can replicate the core Russian findings: being tested now, but not settled.

The structural problem with the evidence base is that nearly all human work flows through a single research program with a clear stake in positive results. That's not a fraud accusation. It's a methodological observation. Replication across independent groups is how biology becomes knowledge. Epitalon hasn't been through that process yet.

Epitalon is more interesting than the most aggressive skeptics allow and considerably less proven than the longevity marketing claims. The in vitro telomerase data is real. The retinitis pigmentosa trial is real. The rodent maximum-lifespan extension is real. The melatonin signal is plausible.

What's missing is the part that would actually matter for the decisions readers face. No independent, blinded, multicenter human trial. No long-term safety follow-up. No pharmacokinetic profile. No resolution of the cancer-cell mechanism question. No regulatory clearance.

For researchers, this is a peptide worth studying carefully, and the recent mechanistic work suggests there's genuine biology here. For consumers reading longevity content that quotes the 4.1-fold mortality reduction as if it settled the question, the more accurate reading is that the field is still at the stage where rigorous human trials would need to be designed, funded, and run before stronger claims could honestly be made.

What those trials would need to look like is straightforward in principle: dose-ranging studies establishing pharmacokinetics in healthy adults, then placebo-controlled trials in aging populations with prespecified endpoints. Telomere length measured by validated assays. All-cause mortality. Validated biological age clocks. Cancer incidence as a safety endpoint, given the ALT finding. Multi-site. Pre-registered. Independent of the original developers.

None of that exists yet. The peptide is being sold and consumed at scale anyway. That gap is the story.